Primary Biliary Cholangitis Pipeline Report 2026: 25+ Therapies from 20+ Companies, Led by Saroglitazar and CNP-104
Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Primary Biliary Cholangitis - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.
Primary Biliary Cholangitis Pipeline Landscape
The report provides a comprehensive analysis of the global Primary Biliary Cholangitis (PBC) pipeline, covering more than 20 companies and over 25 pipeline drugs. It reviews clinical and nonclinical candidates, including late-stage, mid-stage, early-stage, preclinical, discovery, discontinued, and inactive products. The analysis also evaluates Primary Biliary Cholangitis therapies by development phase, product type, route of administration, and molecule type.
PBC is a chronic, progressive autoimmune cholestatic liver disease involving immune-mediated damage to the intrahepatic bile ducts. Progressive bile duct injury can cause cholestasis, inflammation, fibrosis, cirrhosis, and liver failure. PBC is more prevalent among middle-aged women, and patients may initially be asymptomatic. Common clinical features include fatigue, pruritus, right upper abdominal discomfort, dry eyes and mouth, skin hyperpigmentation, xanthomas, jaundice, edema, and weight loss.
The disease is associated with genetic susceptibility, environmental triggers, and an abnormal immune response targeting bile duct cells. Current treatment strategies focus on slowing disease progression, improving bile flow, controlling symptoms, and managing complications. Ursodeoxycholic acid (UDCA) is commonly used as first-line therapy, while additional treatment options may be considered for patients with an inadequate response or intolerance. Liver transplantation may be required in advanced disease.
Primary Biliary Cholangitis Market and Pipeline Analysis
The report examines the current treatment landscape, unmet medical needs, clinical development trends, and growth opportunities in Primary Biliary Cholangitis research and development. Drug profiles include mechanisms of action, clinical study information, regulatory milestones, product development activities, collaborations, licensing agreements, mergers and acquisitions, funding, and regulatory designations.
Companies and academic organizations are investigating novel approaches intended to address immune dysfunction, cholestasis, inflammation, fibrosis, lipid metabolism, and bile acid homeostasis. The report assesses how these emerging therapies may influence future treatment pathways and the competitive Primary Biliary Cholangitis market.
Selected Emerging Primary Biliary Cholangitis Drugs
Therapeutic Assessment
The Primary Biliary Cholangitis pipeline assessment segments products across the following development categories:
Pipeline drugs are also evaluated by route of administration, including oral, subcutaneous, intravenous, and parenteral routes. Molecule types covered include oligonucleotides, peptides, and small molecules. Product categories include monotherapy, combination therapy, and candidates that may be developed in both settings.
Pipeline Development and Competitive Intelligence
The report analyzes clinical trials, development status, pharmacological activity, emerging technologies, and recent industry developments. It also reviews collaborations between industry participants and academic institutions, licensing transactions, acquisitions, mergers, and other strategic activities shaping the Primary Biliary Cholangitis treatment pipeline.
Key areas of analysis include:
Key Companies and Pipeline Products
Companies active in the Primary Biliary Cholangitis pipeline include Zydus Therapeutics Inc., COUR Pharmaceutical Development Company, Inc., Kowa Research Institute, Inc., Parvus Therapeutics, Inc., Calliditas Therapeutics Suisse SA, HighTide Biopharma Pty Ltd, Mirum Pharmaceuticals, Inc., and Hepagene.
Notable pipeline products include Saroglitazar, CNP-104, Pemafibrate, PVT201, Setanaxib, HTD1801, Volixibat, and HPG1860. Together, these candidates represent a range of therapeutic strategies intended to improve clinical outcomes and address persistent unmet needs in Primary Biliary Cholangitis treatment.
Key Topics Covered:
Introduction
Executive Summary
Primary Biliary Cholangitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Primary Biliary Cholangitis - Analytical Perspective
Late Stage Products (Phase III)
Saroglitazar: Zydus Therapeutics Inc.
Mid Stage Products (Phase II)
CNP-104: COUR Pharmaceutical Development Company, Inc.
Early Stage Products (Phase I)
Preclinical and Discovery Stage Products
Inactive Products
Primary Biliary Cholangitis Key Companies
Primary Biliary Cholangitis Key Products
Primary Biliary Cholangitis - Unmet Needs
Primary Biliary Cholangitis - Market Drivers and Barriers
Primary Biliary Cholangitis - Future Perspectives and Conclusion
Primary Biliary Cholangitis Analyst Views
Appendix
List of Tables [12]
List of Figures [12]
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/7qxiks
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.